Mechanism and Spectrum of Activity
Lincosamides are primarily bacteriostatic, though they can act as bactericidal agents at high concentrations. Their mechanism involves the inhibition of bacterial protein synthesis: they bind to the 50S ribosomal subunit (similar to macrolides) and block peptide bond formation during the translocation step.
Their antimicrobial spectrum includes:
- Gram-positive cocci: Staphylococci (including penicillinase-producing and resistant strains), streptococci, and pneumococci.
- Gram-positive bacilli: Corynebacterium diphtheriae.
- Anaerobes: Clostridium perfringens, Clostridium tetani, and Bacteroides fragilis.
- Atypical pathogens: Mycoplasma species.
Pharmacokinetics and Clinical Indications
Both drugs in this class are acid-stable in the stomach. Their key pharmacokinetic hallmark is a strong tissue tropism for bone and joints, where they achieve therapeutic concentrations.
Lincosamides are used as second-line (reserve) antibiotics. Primary indications include:
- Bone and joint infections: Osteomyelitis, septic arthritis.
- Respiratory tract and ENT infections: Pneumonia, tonsillopharyngitis, otitis media.
- Skin and soft tissue infections: Furunculosis, pyoderma.
- Intra-abdominal and pelvic infections: Conditions where anaerobic flora play a major pathogenetic role.
Drug Profiles: Lincomycin and Clindamycin
Lincomycin is a natural antibiotic produced by Streptomyces lincolnensis. Its absorption and bioavailability are significantly reduced by food intake; therefore, it must be administered strictly 1 hour before meals (every 8 hours orally) or parenterally (every 12 hours). Topical application 2–3 times daily is also available.
Clindamycin is a semisynthetic analogue with greater antimicrobial potency than lincomycin. Its primary advantages include:
- High oral bioavailability (approximately 90%).
- Absorption is unaffected by food.
- A half-life yielding a duration of action of about 6 hours.
Clindamycin is a drug of choice for severe anaerobic infections (especially Bacteroides species) and mixed flora. Additionally, it is effective against protozoa, including Pneumocystis jirovecii, Toxoplasma gondii, and Plasmodium species. In specific regimens, it is combined with quinine (for chloroquine-resistant falciparum malaria) or pyrimethamine (for toxoplasmosis).
Safety Profile and Adverse Effects
Lincosamide therapy can be accompanied by several adverse reactions. Common side effects include gastrointestinal distress (nausea, vomiting, diarrhea, abdominal pain), allergic reactions, and hematotoxicity (transient neutropenia and thrombocytopenia).
Pseudomembranous colitis is the most severe and specific complication of lincosamide therapy. This is a form of superinfection resulting from the suppression of normal gut flora by the antibiotic.
Pathogenesis of the complication:
- Uncontrolled overgrowth of Clostridioides difficile (a bacterium that is normally a minor component of the intestinal microbiome).
- The pathogen actively produces cytotoxins (Toxin A and Toxin B).
- The cytotoxins damage the intestinal epithelial lining, causing mucosal ulceration and pseudomembrane formation.
Clinically, the colitis presents with severe watery diarrhea and fever. Treatment involves discontinuation of the offending agent, supportive hydration, and targeted antibiotics active against C. difficile: oral metronidazole (historical/alternative) or oral vancomycin/fidaxomicin as first-line options.